BOLT Bolt Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BOLT

Price (delayed)

$1.11

Market cap

$42.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.83

Enterprise value

$49.97M

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach ...

Highlights
The revenue rose by 37% YoY and by 9% QoQ
Bolt Biotherapeutics's gross profit has increased by 37% YoY and by 9% from the previous quarter
The equity is down by 34% YoY and by 12% from the previous quarter
The quick ratio has contracted by 31% YoY and by 22% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://boltbio.com
Peers: NR NOV FTI GEOS

Key stats

What are the main financial stats of BOLT
Market
Shares outstanding
38.13M
Market cap
$42.32M
Enterprise value
$49.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
5.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.34
Earnings
Revenue
$7.88M
EBIT
-$69.2M
EBITDA
-$64.39M
Free cash flow
-$69.73M
Per share
EPS
-$1.83
Free cash flow per share
-$1.84
Book value per share
$2.97
Revenue per share
$0.21
TBVPS
$4.23
Balance sheet
Total assets
$159.78M
Total liabilities
$47.04M
Debt
$20.22M
Equity
$112.74M
Working capital
$85.25M
Liquidity
Debt to equity
0.18
Current ratio
5.17
Quick ratio
5.08
Net debt/EBITDA
-0.12
Margins
EBITDA margin
-817.6%
Gross margin
100%
Net margin
-878.6%
Operating margin
-967.4%
Efficiency
Return on assets
-37.8%
Return on equity
-51.2%
Return on invested capital
-40.2%
Return on capital employed
-49.7%
Return on sales
-878.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BOLT stock price

How has the Bolt Biotherapeutics stock price performed over time
Intraday
0.91%
1 week
-6.72%
1 month
-26%
1 year
-28.85%
YTD
-0.89%
QTD
-20.71%

Financial performance

How have Bolt Biotherapeutics's revenue and profit performed over time
Revenue
$7.88M
Gross profit
$7.88M
Operating income
-$76.2M
Net income
-$69.2M
Gross margin
100%
Net margin
-878.6%
The net margin has grown by 43% YoY and by 11% from the previous quarter
Bolt Biotherapeutics's operating margin has increased by 39% YoY and by 10% from the previous quarter
The revenue rose by 37% YoY and by 9% QoQ
Bolt Biotherapeutics's gross profit has increased by 37% YoY and by 9% from the previous quarter

Growth

What is Bolt Biotherapeutics's growth rate over time

Valuation

What is Bolt Biotherapeutics stock price valuation
P/E
N/A
P/B
0.37
P/S
5.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.34
The EPS has grown by 22% YoY and by 3.2% from the previous quarter
The equity is down by 34% YoY and by 12% from the previous quarter
BOLT's P/B is 23% above its last 4 quarters average of 0.3
The revenue rose by 37% YoY and by 9% QoQ
The stock's P/S is 17% less than its last 4 quarters average of 6.4

Efficiency

How efficient is Bolt Biotherapeutics business performance
The ROS has grown by 43% YoY and by 11% from the previous quarter
The ROE fell by 16% YoY and by 8% QoQ
Bolt Biotherapeutics's ROA has decreased by 9% YoY and by 6% from the previous quarter
Bolt Biotherapeutics's ROIC has decreased by 7% from the previous quarter and by 6% YoY

Dividends

What is BOLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BOLT.

Financial health

How did Bolt Biotherapeutics financials performed over time
The quick ratio has contracted by 31% YoY and by 22% from the previous quarter
The company's current ratio fell by 31% YoY and by 23% QoQ
The debt is 82% less than the equity
BOLT's debt to equity is up by 38% YoY and by 13% from the previous quarter
The equity is down by 34% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.